MIRM today
$94.69+$0.08 (+0.09%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourLeaning Bullish
15 minAscending Triangle
5 minConsolidating
Daily trend turns up above $104.66
Key levels
Resistance$103.28
Resistance$98.97
Support$93.57
Support$85.84
Latest news & SEC filings
AnalystCitigroup keeps Buy rating on Mirum Pharmaceuticals, lifts target to $194
ProductMirum Pharmaceuticals says AZURE-4 Phase 3 study met its primary endpoint
All MIRM news →About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company that develops and sells therapies for rare diseases. Its marketed medicines include Livmarli, used for cholestatic itching in Alagille syndrome and in progressive familial intrahepatic cholestasis, Ctexli for cerebrotendinous xanthomatosis, and Cholbam for certain inherited bile acid and peroxisomal conditions. Its pipeline features volixibat for two adult cholestatic liver diseases, brelovitug for chronic hepatitis D, and MRM-3379 for fragile X syndrome. Mirum sells directly across the United States, Canada, and parts of Europe, and works with partners in other regions.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
Mirum Pharmaceuticals, Inc. (MIRM)
What Is the Price Target for MIRM?
SEPT Low Target
$130.00
SEPT Mid Target
$155.00
SEPT High Target
$202.00
Analyst Consensus
$155.00
Is MIRM a Buy or Sell Right Now?
Thesis
- •Revenue growing 54.7% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MIRM.
Start Free Trial →Is MIRM Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$155.00
17
Moat Score
NONE
5/9
Piotroski Score
5.2
Altman Z-Score
What Is Smart Money Doing with MIRM?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Peetz Christopher | director officer | Buy | 20,000 | $59K | Nov 4, 2026 |
| Peetz Christopher | director officer | Sale | 20,000 | $1.8M | Nov 4, 2026 |
| Peetz Christopher | director officer | Buy | 5,305 | $102K | Oct 6, 2026 |
| Peetz Christopher | director officer | Buy | 6,892 | $109K | Oct 6, 2026 |
| Peetz Christopher | director officer | Buy | 30,000 | $88K | Sep 1, 2026 |
| Peetz Christopher | director officer | Sale | 8,312 | $815K | Sep 1, 2026 |
| Peetz Christopher | director officer | Sale | 21,688 | $2.1M | Sep 1, 2026 |
| BJERKHOLT ERIC | officer | Buy | 2,393 | $63K | Jun 9, 2026 |
| BJERKHOLT ERIC | officer | Sale | 2,258 | $210K | Jun 8, 2026 |
| BJERKHOLT ERIC | officer | Sale | 1,175 | $110K | Jun 8, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MIRM Growth Story
Revenue YoY
54.7%
3yr Revenue CAGR
89.1%
EPS Growth YoY
74.59%
FCF Growth YoY
488.0%
Revenue Trend
STRONG
Dark Pool Trades for MIRM
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MIRM, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:59:02 | $93.70 | 1,200 | $$112K | SELL |
| 14:53:26 | $93.39 | 4,279 | $$400K | SELL |
| 21:00:27 | $94.61 | 1,567 | $$148K | BUY |
| 21:00:27 | $94.61 | 1,153 | $$109K | BUY |
| 19:34:55 | $94.42 | 1,216 | $$115K | BUY |
5 dark pool trades shown · $$884K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About MIRM
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for MIRM. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $MIRM (Mirum Pharmaceuticals, Inc.) Price: $123.00 | Zone: $101.15 to $124.44 Conviction: HIGH | Analyst upside: +17.9% Near resistance (94% of range) — breakout watch. Strong positive...
Join 3,500+ traders discussing MIRM in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Mirum Pharmaceuticals, Inc. (MIRM) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MIRM — frequently asked questions
What is MIRM stock price today?
Mirum Pharmaceuticals, Inc. (MIRM) is at $94.69, up 0.09% (+$0.08) at the Nov 12, 2026 close.
Why is MIRM stock moving today?
Latest MIRM news — Nov 11, 2026: Citigroup keeps Buy rating on Mirum Pharmaceuticals, lifts target to $194 · Nov 10, 2026: Mirum Pharmaceuticals says AZURE-4 Phase 3 study met its primary endpoint
Why did MIRM stock move on Oct 26, 2026?
Mirum Pharmaceuticals shares rose 2.57% to close at $83.47 after the company announced that its Phase 2 PROGRESS trial of ATEBRIOZ in children with FOP met its goals, with positive results reported. The company also released Cohort 2 results from the pivotal PROGRESS study, reinforcing the drug's potential in a late-stage setting.
What is the MIRM price target?
The average analyst price target for MIRM is $155.00, ranging from $130 to $202, based on 13 analysts. Latest: Citigroup maintains on Nov 11, 2026.
What do analysts rate MIRM?
Analyst ratings for MIRM: 0 Buy, 36 Hold, 0 Sell — consensus Hold.
Did MIRM beat earnings?
MIRM last reported on Nov 3, 2026: EPS -$0.87 vs -$0.49 expected — a miss of 78.7%.
Does MIRM pay a dividend?
MIRM does not currently pay a dividend.
What are MIRM support and resistance levels?
Support: $93.57, $85.84, $80.24. Resistance: $98.97, $103.28, $109.75.
What are insiders doing with MIRM?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on MIRM?
Nov 11, 2026: Citigroup keeps Buy rating on Mirum Pharmaceuticals, lifts target to $194 · Nov 10, 2026: Mirum Pharmaceuticals says AZURE-4 Phase 3 study met its primary endpoint